Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

95 results about "Troponin" patented technology

Troponin, or the troponin complex, is a complex of three regulatory proteins (troponin C, troponin I, and troponin T) that is integral to muscle contraction in skeletal muscle and cardiac muscle, but not smooth muscle. Blood troponin levels may be used as a diagnostic marker for stroke, although the sensitivity of this assay is low. Assays of cardiac-specific troponins I and T are extensively used as diagnostic and prognostic indicators in the management of myocardial infarction and acute coronary syndrome.

Preparation method of electrochemical biosensor based on PLL-coated VPAu modified nuclear track membrane

The invention provides a preparation method of an electrochemical biosensor based on a PLL-coated VPAu modified nuclear track membrane, and belongs to the field of electrochemical biosensing analysis. The electrochemical biosensor for detecting troponin is constructed by adsorbing a PLL (at) VPAu composite nanomaterial synthesized by an ultrasonic liquid phase assisted method into a nuclear track membrane pore channel through electrostatic interaction and connecting a specific recognition molecule of a target to the surface of the pore channel modified by the PLL (at) VPAu by utilizing a bonding reaction mechanism. After a target object is captured by the recognition molecules connected to the nuclear track membrane, the effective aperture of the nuclear track membrane nanopores is reduced, and the electrochemical workstation can convert the biological behavior into an electric signal, so that high-sensitivity and rapid detection of the target protein is realized. The method has very important theoretical and practical significance in the field of medical diagnosis, and a new direction is provided for application of the nuclear track membrane in the field of analysis and detection.
Owner:UNION MEDICAL & PHARM TECH TIANJIN GRP LTD

High-sensitivity cardiac troponin-T electrochemiluminescence detection kit

The invention discloses a high-sensitivity cardiac troponin-T electrochemiluminescence detection kit. The kit comprises a magnetic microsphere reagent coated by a high-sensitivity cardiac troponin-T capture antibody and a high-sensitivity cardiac troponin-T detection antibody reagent labeled by an electrically neutral ruthenium compound, the structural general formula of the electrically neutral ruthenium compound is # imgabs0 # n = 0-9; the magnetic microsphere reagent coated with the high-sensitivity cardiac troponin-T capture antibody comprises a magnetic microsphere coated with the high-sensitivity cardiac troponin-T capture antibody and a diluent; the electrically neutral ruthenium compound labeled high-sensitivity cardiac troponin-T detection antibody reagent comprises an electrically neutral ruthenium compound labeled high-sensitivity cardiac troponin-T detection antibody and a diluent; the diluent is prepared from piperazine-1, 4-diethyl sulfonic acid or 3-(N-morpholinyl)-2-hydroxy propanesulfonic acid. When the high-sensitivity cardiac troponin-T electrochemiluminescence detection kit is used for detection, a reaction system does not contain streptavidin coated magnetic beads or biotinylated antibodies, so that interference of biotin in a sample is avoided.
Owner:ACCUCISE DIAGNOSTICS INC

Preparation and application of novel Fe monatomic nano-enzyme

According to the preparation and application of the novel Fe monatomic nano enzyme, mesoporous silica is used as a substrate material, the surface of the substrate material is coated with a layer of dopamine and hemin, then high-temperature calcination is performed to form the monatomic nano enzyme Fe-N-C, then the monatomic nano enzyme Fe-N-C is used as a signal reporter molecule of a lateral flow chromatography test strip, and the application of the monatomic nano enzyme Fe-N-C in the lateral flow chromatography test strip is realized. A labeled antibody is connected to the surface of the antibody, so that rapid detection of cardiac troponin I (cTnI) is realized. In the monatomic nano-enzyme, dopamine mainly provides a carbon source, heme mainly provides Fe and a nitrogen source, the larger specific surface area of mesopores provides abundant sites for the monatomic nano-enzyme, and the contact area of the monatomic nano-enzyme and a substrate is increased, so that the enzyme activity is improved. In conclusion, the material has a large specific surface area and relatively high enzyme activity. And finally, quickly detecting the biomarker cTnI after the test strip platform is integrated.
Owner:重庆医科大学国际体外诊断研究院

Multimodal continuous monitoring device

A wearable heart monitoring device includes a carrier and a housing. The carrier includes a first electrode defining a sensor configured to measure at least one of b-type natriuretic peptide (BNP), N-terminal pro b-type natriuretic peptide (NT-proBNP), or Troponin. Moreover, a second electrode is configured to measure at least one of parameter associated with a heart, heart disease, or heart disease treatment, of a patient wearing the heart monitoring device. The housing includes an adhesive thereon. The housing is coupled to the carrier. Moreover, the housing contains a controller communicably coupled to the first electrode and the second electrode, memory coupled to the controller, and a communication interface communicably coupled to the controller.
Owner:KILELE HEALTH

Anti-cardiac troponin I antibody and application thereof

The invention discloses an anti-cardiac troponin I antibody and application thereof, and relates to the field of antibodies. The anti-cardiac troponin I antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of cardiac troponin I, and has good affinity or activity.
Owner:DONGGUAN PENGZHI BIOTECH CO LTD

Cardiovascular marker substance control product and preparation method thereof

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.
Owner:GUANGZHOU TEBSUN BIO TECH DEV

Cardiac troponin I fragment, product prepared from cardiac troponin I fragment and application of cardiac troponin I fragment

The invention belongs to the field of biological detection, and particularly relates to a cardiac troponin I fragment, a product prepared from the cardiac troponin I fragment and application of the cardiac troponin I fragment. According to the specific technical scheme, the protein fragment comprises a cTnI (31-164) protein fragment, an HSP65 (187-375) protein fragment and a protein fragment combination. The invention provides a protein antigen or composition for detecting acute myocardial infarction, the detection specificity and sensitivity are ideal, and the protein antigen or composition can be further prepared into related reagents or kits according to needs.
Owner:SHANGHAI XIANSAI BIOTECHNOLOGY CO LTD

Cardiac troponin I specific antibody, kit and application

The invention provides an antibody specifically targeting cardiac troponin I. The invention further provides a preparation method of the antibody. The invention further provides an antibody pair comprising the antibody and a kit. The invention further provides the use of these antibodies to detect the level of cardiac troponin I and to diagnose myocardial damage.
Owner:SHENZHEN MINDRAY BIO MEDICAL ELECTRONICS CO LTD

Skp2 gene therapy using aav vectors

PendingCN120603602AVectorsPeptide/protein ingredientsCoronary arteriesPlasmodium falciparum
Provided herein are gene therapies against PKP2 (spot phenanthrin protein-2), such as the use of adeno-associated virus (AAV) vectors. The promoter of the vector can be an MHCK7 promoter or a cardiac troponin T (cTnT2) promoter. The capsid may be AAV9 or AAVrh.74 or a capsid protein comprising AAV9 or AAVrh.74, or a functional variant thereof. Other promoters or capsids may be used. Also provided are methods of treatment, such as by intravenous, intracoronary, intracarotid, or intracardiac administration of the rAAV vector, as well as other compositions and methods.
Owner:SPACECRAFT SEVEN LLC

Preparation of a sandwich electrochemical immunosensor for cardiac troponin I

The present invention belongs to the fields of novel nanocomposites, immunoassays, and biosensor technologies, and provides a method for preparing a sandwich-type electrochemical immunosensor for cardiac troponin I. The present invention uses highly conductive, gold-particle-loaded, hierarchically porous nitrogen-doped carbon nanotubes (Au NPs / N-CNTs) as a substrate and mesoporous palladium nitrogen nanocubes (meso-PdN NCs) as an electrochemical signal amplification platform to achieve quantitative detection of cardiac troponin I (CTnI) antigen. This method has the advantages of strong specificity, high sensitivity, and a low detection limit, and has important scientific significance and application value for the detection of acute myocardial infarction (AMI).
Owner:SHANDONG UNIV OF TECH

A cardiovascular marker quality control and a preparation method thereof

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.
Owner:GUANGZHOU TEBSUN BIO TECH DEV

Hypersensitive troponin T detection method and kit based on spatial proximity chemiluminescence

The invention relates to the technical field of biological detection, in particular to a hypersensitive troponin T detection method and kit based on spatial proximity chemiluminescence. The method comprises the following steps: mixing and reacting a to-be-detected sample, an enzyme marker and a luminous marker to obtain a reactant, adding a luminous auxiliary agent and a triggering agent, and detecting the luminous value of the reactant to obtain the content of the hypersensitive troponin T in the to-be-detected sample, the enzyme marker is a first anti-cTnT monoclonal antibody marked by horse radish peroxidase, and the luminous marker is a second anti-cTnT monoclonal antibody marked by 9, 10-dihydroacridine. The detection method disclosed by the invention is high in sensitivity, good in specificity and good in stability, and is nontoxic and harmless to the environment and a human body; carrier and washing steps are not needed in the detection process, cost is low, efficiency is high, and accuracy is good; the kit has the advantages of few components, simple production process, low production cost and easiness in large-scale production and full-automatic detection.
Owner:CHINA MEDICAL BIOTECHNOLOGY (BEIJING) CO LTD

Tropnin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction

PendingUS20250362308A1Disease diagnosisBiological testingCardiac myosinCardiac infarction
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC

Method for constructing label-free immune platform through enzyme / antibody non-covalent modification of ZnNFs and ZnNPs

The invention relates to a method for constructing a label-free immune platform through enzyme / antibody non-covalent modification of ZnNFs and ZnNPs, and belongs to the technical field of nano biosensing. The method comprises the following steps: respectively synthesizing ZnNFs and ZnNPs under the conditions of 25 DEG C and 4 DEG C based on a zinc nitrate and 3-methyl-1H-1, 2, 4-triazole (Hmtz) one-pot synthesis method, and constructing a completely non-labeled enzyme-linked immunosorbent assay platform to realize the detection of cardiac troponin I. The ZnNFs and the ZnNPs have the advantages of simple synthesis, uniform size, strong adsorption capacity and the like, the newly constructed magnetic separation complete non-labeled enzyme-linked immunosorbent assay platform successfully realizes the detection of cardiac troponin I and new coronavirus N protein in a complex environment, and the standard recovery rate experiment is within the standard error range. The sensing platform has huge potential in the aspect of disease diagnosis.
Owner:NANJING TECH UNIV

Noninvasive troponin monitoring system

The invention discloses a non-invasive troponin monitoring system, which comprises a signal acquisition module, a filtering processing module, a feature extraction module, a clustering result generation module, a clustering result generation module, a clustering result generation module, a clustering result generation module, a clustering result generation module, a clustering result generation module and a clustering result generation module, wherein the signal acquisition module collects bio-electricity signals and the like to generate a data set, and the filtering processing module calculates a signal-to-noise ratio and adjusts filter bandwidth to output filtering signals. The data fusion module synchronizes the electrocardiogram period to integrate the feature vector, and the calibration output module monitors the environment change and generates a calibrated feature vector. According to the non-invasive troponin monitoring system, an original data set is generated by collecting multi-dimensional signals of a human body and environmental parameters. A dynamic filtering technology is utilized to optimize a signal-to-noise ratio, accurately extract time domain and frequency domain features and perform clustering analysis, an electrocardiogram period is synchronously analyzed to realize data fusion, multi-dimensional feature vectors are generated, calibration is performed in combination with environment monitoring data, interference is effectively eliminated, and high precision and stability of a troponin monitoring result are improved.
Owner:HANGZHOU NORMAL UNIVERSITY

Anti-troponin I monoclonal antibody and application thereof

The invention relates to the field of antibodies, in particular to an anti-troponin I monoclonal antibody and application thereof, performance analysis of a purified electrophoretogram of the antibody and a kit coupled with a monoclonal antibody HK401 coated magnetic particle component shows that the monoclonal antibody has excellent performance in cTni detection, and the cTni detection sensitivity is high. The method can be used as an object for further production and optimization.
Owner:HONGKUI BIOLOGICAL CHINA CO LTD

Use of cardiac troponin and galectin-3 to distinguish between type I and type II myocardial infarction

The present invention provides methods for determining whether a subject suspected of having a myocardial infarction is suffering from type I or type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on a decision tree-based algorithm to process the subject's gender, age, and cardiac troponin concentration, as well as the subject's galectin-3 (Gal-3) concentration.
Owner:ABBOTT LAB INC

Nucleic acid aptamer specifically combined with cardiac troponin I as well as screening method and application of nucleic acid aptamer

The invention discloses a nucleic acid aptamer specifically combined with cardiac troponin I as well as a screening method and application of the nucleic acid aptamer. Belongs to the technical field of molecular biological detection analysis. According to the invention, molecular docking simulation and circular dichroism are used for screening the aptamer which is most stable after being combined with cardiac troponin I and has the largest conformational change. The aptamer Apt-36 obtained by screening is fixed on the surface of a gold electrode after being modified with a disulfide bond and methylene blue, and an electrochemical aptamer sensor is constructed. After the cardiac troponin I is added, the aptamer is induced to generate conformational change, the distance between the redox reporter molecule and the surface of the electrode is changed, and an electrochemical signal easy to detect is generated, so that the cardiac troponin I is analyzed and detected. The sensitivity of the sensor is effectively improved, the detection limit is as low as 1 pg / mL, and the sensor can be directly used for detecting cardiac troponin I in a complex biological sample. The kit has a wide application prospect in clinical diagnosis of acute myocardial infarction.
Owner:FUZHOU UNIV

Use of cardiac troponin and galectin-3 for differentiating type I and type II cardiac infarction

The present invention provides methods for determining whether a subject suspected of having myocardial infarction is experiencing type I myocardial infarction or type II myocardial infarction. In particular, systems and methods are provided for processing the gender, age, and cardiac troponin concentration of a subject, as well as the galectin-3 (Gal-3) concentration of a subject, employing probability scoring based on a decision tree algorithm.
Owner:ABBOTT LAB INC

Peptide for treating heart failure

Provided herein is a peptide capable of inhibiting a phosphodiesterase-4 (PDE4) protein from binding to a troponin I (TPNI) protein, wherein the peptide has a maximum length of 24 amino acids. Also provided are nucleic acid sequences encoding the peptide, expression constructs and vectors comprising the nucleic acid sequences, conjugates comprising the peptide covalently linked to a delivery group, delivery particles comprising the peptide, and pharmaceutical compositions comprising the peptide. The peptide, nucleic acid sequences, expression constructs, vectors, conjugates, delivery particles, and pharmaceutical compositions may be used as medicaments, for example in the treatment or prevention of diastolic dysfunction, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or hypertrophic cardiomyopathy.
Owner:OXFORD UNIVERSITY INNOVATION LTD

Traditional Chinese medicine composition for acute myocardial infarction in PCI (percutaneous coronary intervention) postoperative recovery phase

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.
Owner:THE SECOND AFFILIATED HOSPITAL OF JIANGXI UNIV OF TRADITIONAL CHINESE MEDICINE

Application of PTPRM in the treatment and / or prevention of septic cardiomyopathy

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.
Owner:GENERAL HOSPITAL OF PLA

Pregnancy disease risk prediction method and device based on biochemical indexes and program product

The invention relates to the field of intelligent medical treatment, in particular to a pregnancy disease risk prediction method and device based on biochemical indexes and a program product. Comprising the following steps: S1, acquiring serum biochemical index data of a pregnant woman; s2, comparing the serum biochemical indexes with a preset threshold value; the serum biochemical indexes include aspartate aminotransferase, total protein, albumin, lactic dehydrogenase, alkaline phosphatase, total bile acid, creatine kinase, blood sugar, urea nitrogen, uric acid, creatinine, glomerular filtration rate, potassium, chlorine, total calcium, serum magnesium, inorganic phosphorus, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and homocysteine. When one or more of the myoglobin, the hypersensitive troponin I, the prealbumin, the cystatin C and the creatine kinase isoenzyme MB are abnormal, judging that the pregnancy eclampsia exists. The method is simple, convenient and rapid to operate and low in cost, can be clinically popularized to predict the health state of the pregnant woman on a large scale, and has good clinical value.
Owner:BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV

B-cell lymphoma 2-associated immortalized gene 3 (BAG3) gene therapy using AAV vectors

The present invention provides a gene therapy, for example, using BAG3 (B cell lymphoma 2-associated immortalized gene 3) of an adeno-associated virus (AAV) vector. The promoter of the vector can be an MHCK7 promoter, a heart troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or a functional variant thereof. Other promoters or capsids may be used. The invention further provides methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, as well as other compositions and methods.
Owner:SPACECRAFT SEVEN LLC

Automated sample preparation system implemented within a disposable cartridge

According to this invention, there is provided an automated sample preparation system implemented within a disposable cartridge. The system utilizes finger prick blood or venous blood as an input sample and performs various sample processing steps, including fluidic metering, fluidic routing, and reagent storage with an integrated biosensor. The architecture, of this system, enables efficient and accurate testing of blood parameters, hematology parameters such as CBC, CD4-T cells count, but not limited to, Complete Blood Cell Count (CBC) and measurement of biomarkers such as Troponin, IL-6, Procalcitonin, but not limited to, CRP, Procalcitonin, and IL-6 through ELISA and is flexible to implement other electrochemistry techniques.
Owner:MICROX LABS INC

Promoter-enhancer sequences of the human troponin T gene for selective expression in cardiomyocytes

This invention describes a novel gene regulatory sequence containing the promoter and enhancer sequences of the human cardiac troponin T gene (TNNT2) that selectively induces expression in cardiomyocytes. This novel TNNT2 promoter / enhancer composition can be used to induce adeno-associated virus gene expression, construct cell-type-specific expression vectors, or perform cardiac-specific transgenesis. The use of this novel promoter / enhancer composition is demonstrated by the expression of mAKAP shRNA and a mAKAP-derived anchor-disrupting peptide useful for the treatment of heart failure.
Owner:CRI BIOTECH INC

Chemiluminescence immunoassay method for high-sensitivity detection of cardiac troponin I

The invention relates to the technical field of immunoassay, and discloses a chemiluminescence immunoassay method for high-sensitivity detection of cardiac troponin I. The chemiluminescence immunoassay method comprises the following steps: fixing an anti-cardiac troponin I capture antibody based on a solid phase carrier; a sample to be detected is in contact with the solid phase carrier coated with the capture antibody, a detection antibody is added, the detection antibody is connected with a signal marker, and the signal marker is a compound formed by loading alkaline phosphatase on a nano material or is the nano material; a chemiluminescent substrate is added, and the chemiluminescent substrate is a compound based on 1, 2-dioxetane; detecting a chemiluminescence signal so as to quantify cardiac troponin I; according to the invention, the problem of non-uniform detection of degradation fragments is solved, and the diagnosis window period is prolonged; meanwhile, extremely high detection sensitivity, signal-to-noise ratio and stability are realized, and the kit is suitable for early and accurate diagnosis of myocardial injury.
Owner:HAINAN VOCATIONAL COLLEGE OF SCI & TECH

High-risk chest pain prediction analysis method and device based on machine learning and readable medium

The invention discloses a high-risk chest pain prediction analysis method and device based on machine learning and a readable medium, and relates to the field of data analysis, and the method comprises the steps: carrying out the data enhancement and denoising of a data set through employing an SMOTE-ENN; screening baseline features in the processed data set by using a sequence forward selection method based on feature importance of a tree model, and verifying the validity of the screened features by using a Boruta algorithm to obtain important features; acquiring values of important features of a to-be-predicted chest pain patient, and inputting the values into the trained chest pain risk layering prediction model to obtain a corresponding chest pain risk layering result; and determining the maximum value of troponin in the important features as the feature influencing the prediction result of the chest pain risk hierarchical prediction model through SHAP analysis, analyzing the relationship between the maximum value of troponin and the death rate in the hospital, and determining the numerical value of the maximum value of troponin corresponding to the maximum death rate in the hospital. The problem of low accuracy of chest pain risk layered prediction is solved.
Owner:FUJIAN PROVINCIAL HOSPITAL